Skip to main content

Table 2 TRK inhibitors currently in clinical development

From: Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers

Drug name Targets Development stage Clinical trial identifier Company
LOXO-101 (larotrectinib) NTRK1/2/3 Phase II NCT02122913
NCT02637687
NCT02576431
NCT03213704
Loxo Oncology
LOXO-195 NTRK1/2/3 (resistant) Phase I/II NCT03215511 Loxo Oncology
RXDX-101 (entrectinib) NTRK1/2/3, ALK, ROS1 Phase I/II,
Phase II,
Phase I/Ib
NCT02097810
NCT02568267
NCT02650401
Ignyta
TPX-0005 (ropotrectinib) NTRK1/2/3, ALK, ROS1 (resistant), JAK2, SRC, DDR1, FAK Phase I/II NCT03093116 TP Therapeutics
LY2801653 (merestinib) NTRK1/2/3, MET, MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2, MKNK1/2 Phase II NCT02920996 Eli Lilly and Company
DS-6051b NTRK1/2/3, ROS1 Phase I NCT02675491
NCT02279433
Daiichi Sankyo
PLX7486 NTRK1/2/3, CSF1R Phase I NCT01804530 Plexxikon/Daiichi Sankyo
MGCD516 (sitravatinib) NTRK1/2/3, MET, KIT, PDGFRA, KDR, DDR2, RET, CBL Phase I/Ib NCT02219711 Mirati Therapeutics